Watch VVOS. Know when insiders buy.
One email the day a filing lands. Free.
VVOS
Vivos Therapeutics, Inc.
0.15
+0.00 +2.01%
USD · close Oct 2
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $3.1MP/E —DIV YIELD —FCF YIELD -621.76%REV TTM $20.9M +45.2%NET INCOME −$25.5MNET CASH $1.2M52W 0.13 – 3.25SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $5.2M | +34.9% | 57.3% | −$4.8M | −$5.5M | — | -0.31 | −$3.1M | $416K | −$3.6M | Aug 14 |
| Q1 2026 · Mar 31 | $5.1M | +70.5% | 59.5% | −$6.6M | −$7.7M | — | -0.52 | −$6M | $18K | −$6M | May 20 |
| Q4 2025 · Dec 31derived | $3.8M | +3.4% | 78.1% | −$6.4M | −$6.9M | — | -0.58 | −$3.8M | $1.5M | −$5.3M | Apr 15 |
| Q3 2025 · Sep 30 | $6.8M | +75.7% | 58.0% | −$4.7M | −$5.4M | — | -0.49 | −$4.2M | −$83K | −$4.1M | Nov 19 |
| Q2 2025 · Jun 30 | $3.8M | −5.8% | 55.2% | −$4.9M | −$5M | — | -0.55 | −$3.5M | $771K | −$4.3M | Aug 14 |
| Q1 2025 · Mar 31 | $3M | −11.8% | 50.0% | −$3.9M | −$3.9M | — | -0.45 | −$3.8M | $122K | −$3.9M | May 20 |
| Q4 2024 · Dec 31derived | $3.7M | +13.9% | 56.7% | −$2.8M | −$2.8M | — | -0.28 | −$2.9M | $165K | −$3.1M | Apr 15 |
| Q3 2024 · Sep 30 | $3.9M | +16.9% | 60.5% | −$2.6M | −$2.6M | — | -0.40 | −$4.2M | $192K | −$4.4M | Nov 19 |
| Q2 2024 · Jun 30 | $4.1M | — | 65.4% | −$1.9M | −$1.9M | — | -0.60 | −$3M | $60K | −$3.1M | Nov 19 |
| Q1 2024 · Mar 31 | $3.4M | — | 56.7% | −$3.8M | −$3.8M | — | -1.63 | −$2.5M | $151K | −$2.7M | Nov 19 |
| Q4 2023 · Dec 31derived | $3.2M | — | 64.3% | −$4.1M | −$4.3M | — | -3.05 | −$2.7M | $165K | −$2.9M | Mar 31 |
| Q3 2023 · Sep 30 | $3.3M | — | 52.9% | −$3.6M | −$2.1M | — | -1.75 | −$2.8M | $154K | −$3M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $17.4M | 60.4% | −$19.9M | −$21.2M | -121.4% | -2.07 | −$15.3M | $2.3M | −$17.6M | — | — |
| FY2024 · to Dec 31 | $15M | 60.0% | −$11.2M | −$11.1M | -74.1% | -2.22 | −$12.7M | $568K | −$13.3M | — | — |
| FY2023 · to Dec 31 | $13.8M | 59.9% | −$17.3M | −$13.6M | -98.4% | -11.14 | −$11.9M | $803K | −$12.7M | — | — |
| FY2022 · to Dec 31 | $16M | 62.5% | −$25M | −$23.8M | -148.8% | -25.90 | −$19.6M | $924K | −$20.5M | — | — |
| FY2021 · to Dec 31 | $16.9M | 74.6% | −$20.4M | −$20.3M | -120.2% | -0.96 | −$15.7M | $2.4M | −$18.1M | — | — |
| FY2020 · to Dec 31 | $13.1M | 79.7% | −$12M | −$12.1M | -92.3% | -1.40 | −$5.7M | $120K | −$5.8M | — | — |
Every number comes from Vivos Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.